Development of future indications for BOTOX.
Since the late 1970s, local injections of BoNT have provided clinical benefit for patients with inappropriately contracting muscles with or without pain or sensory disturbance. Marketing authorization for some BoNTs, depending on country, include core indications of dystonia (blepharospasm and cervical dystonia), large muscle spastic disorders (not yet approved in the United States, e.g., adult post-stroke spasticity and equinus foot deformity), hyperhidrosis and aesthetic. Subsequent development has extended to selected conditions characterized by recurrent or chronic pain (migraine headache), and urologic indications (neurogenic/idiopathic overactive bladder; prostate hyperplasia), with multiple additional opportunities available. Portfolio management requires a careful individual opportunity assessment of scientific and technical aspects (basic science foundation, potential to treat unmet medical need, product-specific risk in specific populations, therapeutic margin/safety profile, and probability of successful registration pathway). This article describes ongoing development targets for BOTOX.
Brin
Mitchell F
MF
Allergan, LLC, 2525 Dupont Drive, Irvine, CA 92612-1599, USA. brin_mitchell@allergan.com
D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D004341:Drug Evaluation / Q000639:trends; D005260:Female; D005544:Forecasting; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy*; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D014570:Urologic Diseases / Q000188:drug therapy*
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A